

Heather A Parsons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1522732/publications.pdf>

Version: 2024-02-01

28
papers

2,104
citations

471509

17
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

4331
citing authors

#	ARTICLE	IF	CITATIONS
1	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	12.8	584
2	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	1.6	251
3	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	1.6	162
4	<i>ESR1</i> Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 993-999.	7.0	152
5	DNA Binding Features of Human POT1. <i>Journal of Biological Chemistry</i> , 2004, 279, 13241-13248.	3.4	139
6	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	7.0	109
7	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	329.8	101
8	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	94
9	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. <i>Clinical Biochemistry</i> , 2015, 48, 993-998.	1.9	91
10	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6205-14.	7.1	69
11	Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 2017, 1-19.	3.0	57
12	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	7.0	50
13	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	1.6	42
14	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. <i>Nature Biomedical Engineering</i> , 2022, 6, 257-266.	22.5	32
15	Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. <i>Npj Breast Cancer</i> , 2019, 5, 46.	5.2	26
16	Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. <i>Clinical Chemistry</i> , 2017, 63, 1605-1613.	3.2	23
17	<i>NDRG1</i> links p53 with proliferation-mediated centrosome homeostasis and genome stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11583-11588.	7.1	21
18	Adjuvant Capecitabine in Triple-Negative Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 36.	7.4	17

#	ARTICLE	IF	CITATIONS
19	Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. <i>Human Pathology</i> , 2014, 45, 1546-1550.	2.0	12
20	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	2.8	11
21	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	8.2	10
22	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. <i>Oncotarget</i> , 2015, 6, 25240-25251.	1.8	9
23	Late Recurrence Following Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1400-1406.	1.6	9
24	Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”? Reply. <i>JAMA Oncology</i> , 2022, 8, 1221.	7.1	8
25	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. <i>JCO Precision Oncology</i> , 2021, 5, 896-903.	3.0	6
26	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e20-e26.	2.4	5
27	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	3.0	5
28	Tamoxifen for 5 years reduced 16-year risk for breast cancer in women at increased risk. <i>Annals of Internal Medicine</i> , 2015, 162, JC11.	3.9	0